GSK and Actelion drop insomnia treatment

pharmafile | January 30, 2011 | News story | Research and Development Actelion, GSK, insomnia 

Actelion and GlaxoSmithKline are to abandon development of phase III insomnia drug almorexant because of problems with side-effects.

Almorexant a dual orexin receptor antagonist,has been discontinued following a review of data from additional clinical studies which were conducted to gather further data on its clinical profile, “including the tolerability profile”.

The companies nevertheless say they “remain committed to conducting further research to better understand the potential of orexin receptor antagonism in sleep disorders and other indications”. 

Actelion has grown very rapidly over the last few years thanks to its pulmonary arterial hypertension blockbuster Tracleer (bosentan), but is needs other drugs to maintain and expand its revenues.

Tracleer brings in the vast majority of the company’s revenues, but faces patent expiry from 2015.

Related Content

GSK shares results from phase 3 trial for gonorrhoea treatment

GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …

GSK’s meningococcal vaccine candidate accepted for FDA review

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …

GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment

GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase …

Latest content